192 related articles for article (PubMed ID: 20682979)
21. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B; Davey R
Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
[TBL] [Abstract][Full Text] [Related]
22. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
23. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
25. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
26. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
Iwatsuki M; Mimori K; Yokobori T; Tanaka F; Tahara K; Inoue H; Baba H; Mori M
J Surg Oncol; 2009 Sep; 100(3):261-6. PubMed ID: 19330779
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
28. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
[TBL] [Abstract][Full Text] [Related]
29. [Expression of livin in gastric cancer and effect of silencing of the livin gene on apoptosis in gastric cancer cells].
Liu P; Wang TS; You SH; Ge HM
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):570-4. PubMed ID: 18210873
[TBL] [Abstract][Full Text] [Related]
30. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
[TBL] [Abstract][Full Text] [Related]
31. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Folkvord S; Flatmark K; Seierstad T; Røe K; Rasmussen H; Ree AH
Radiother Oncol; 2008 Mar; 86(3):428-34. PubMed ID: 18006097
[TBL] [Abstract][Full Text] [Related]
33. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Tseng SC; Huang YC; Chen HJ; Chiu HC; Huang YJ; Wo TY; Weng SH; Lin YW
Biochem Pharmacol; 2013 Feb; 85(4):583-94. PubMed ID: 23228696
[TBL] [Abstract][Full Text] [Related]
34. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
35. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
36. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
37. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
38. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
39. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
40. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
